We speculate that the alterations in the receptor’s turnover induced by mutations in p53 [4,5,6] might modify the mechanism of EGFR/AKT activation, making glioma cells insensitive to changes in the expression and/or the function of TMEM167. This evidence concerns the gene TMEM167A and central nervous system cancer.